For instance, the SAVOR-TIMI 53 trial [15] raised concerns when it observed an increased risk of heart failure hospitalizations associated with the DPP-4 inhibitor saxagliptin, though other studies with different DPP-4 inhibitors, like sitagliptin, found no such association. This evidence concerns the gene DPP4 and heart failure.